The Impact of Transplantation with Deceased Donor Hepatitis C-Positive Kidneys on Survival in Wait-Listed Long-term Dialysis Patients

[Guest guest]

American Journal of Transplantation

Volume 4 Issue 12 Page 2032 - December 2004

doi:10.1046/j.1600-6143.2004.00606.x

The Impact of Transplantation with Deceased Donor Hepatitis C-Positive

Kidneys on Survival in Wait-Listed Long-term Dialysis Patients

C. Abbotta,*, Krista L. Lentineb, Jay R. Buccia, Lawrence Y. Agodoac,

G. sd and Mark A. Schnitzlerb

Whether transplantation of deceased donor kidney allografts from donors with

antibodies against hepatitis C virus (HCV) confers a survival advantage

compared with remaining on the kidney transplant waiting list is not yet

known. We studied 38,270 USRDS Medicare beneficiaries awaiting kidney

transplantation who presented with end-stage renal disease from April 1,

1995 to July 31, 2000. regression was used to compare the adjusted

hazard ratios for death among recipients of kidneys from deceased donors,

and donors with antibodies against hepatitis C (DHCV+), controlling for

demographics and comorbidities. In comparison to staying on the waiting

list, transplantation from DHCV+ was associated with improved survival among

all patients (adjusted hazard ratio for death 0.76, 95% CI 0.60, 0.96). Of

patients receiving DHCV+ kidneys, 52% were themselves hepatitis C antibody

positive (HCV+), so outcomes associated with use of these grafts may have

particular implications for HCV+ transplant candidates. Recommendations for

use of DHCV+ kidneys may require analysis of data not currently collected

from either dialysis or transplant patients. However, transplantation of

DHCV+ kidneys is associated with improved patient survival compared to

remaining wait-listed and dialysis dependent.

[Guest guest]

American Journal of Transplantation

Volume 4 Issue 12 Page 2032 - December 2004

doi:10.1046/j.1600-6143.2004.00606.x

The Impact of Transplantation with Deceased Donor Hepatitis C-Positive

Kidneys on Survival in Wait-Listed Long-term Dialysis Patients

C. Abbotta,*, Krista L. Lentineb, Jay R. Buccia, Lawrence Y. Agodoac,

G. sd and Mark A. Schnitzlerb

Whether transplantation of deceased donor kidney allografts from donors with

antibodies against hepatitis C virus (HCV) confers a survival advantage

compared with remaining on the kidney transplant waiting list is not yet

known. We studied 38,270 USRDS Medicare beneficiaries awaiting kidney

transplantation who presented with end-stage renal disease from April 1,

1995 to July 31, 2000. regression was used to compare the adjusted

hazard ratios for death among recipients of kidneys from deceased donors,

and donors with antibodies against hepatitis C (DHCV+), controlling for

demographics and comorbidities. In comparison to staying on the waiting

list, transplantation from DHCV+ was associated with improved survival among

all patients (adjusted hazard ratio for death 0.76, 95% CI 0.60, 0.96). Of

patients receiving DHCV+ kidneys, 52% were themselves hepatitis C antibody

positive (HCV+), so outcomes associated with use of these grafts may have

particular implications for HCV+ transplant candidates. Recommendations for

use of DHCV+ kidneys may require analysis of data not currently collected

from either dialysis or transplant patients. However, transplantation of

DHCV+ kidneys is associated with improved patient survival compared to

remaining wait-listed and dialysis dependent.

[Guest guest]

American Journal of Transplantation

Volume 4 Issue 12 Page 2032 - December 2004

doi:10.1046/j.1600-6143.2004.00606.x

The Impact of Transplantation with Deceased Donor Hepatitis C-Positive

Kidneys on Survival in Wait-Listed Long-term Dialysis Patients

C. Abbotta,*, Krista L. Lentineb, Jay R. Buccia, Lawrence Y. Agodoac,

G. sd and Mark A. Schnitzlerb

Whether transplantation of deceased donor kidney allografts from donors with

antibodies against hepatitis C virus (HCV) confers a survival advantage

compared with remaining on the kidney transplant waiting list is not yet

known. We studied 38,270 USRDS Medicare beneficiaries awaiting kidney

transplantation who presented with end-stage renal disease from April 1,

1995 to July 31, 2000. regression was used to compare the adjusted

hazard ratios for death among recipients of kidneys from deceased donors,

and donors with antibodies against hepatitis C (DHCV+), controlling for

demographics and comorbidities. In comparison to staying on the waiting

list, transplantation from DHCV+ was associated with improved survival among

all patients (adjusted hazard ratio for death 0.76, 95% CI 0.60, 0.96). Of

patients receiving DHCV+ kidneys, 52% were themselves hepatitis C antibody

positive (HCV+), so outcomes associated with use of these grafts may have

particular implications for HCV+ transplant candidates. Recommendations for

use of DHCV+ kidneys may require analysis of data not currently collected

from either dialysis or transplant patients. However, transplantation of

DHCV+ kidneys is associated with improved patient survival compared to

remaining wait-listed and dialysis dependent.

[Guest guest]

American Journal of Transplantation

Volume 4 Issue 12 Page 2032 - December 2004

doi:10.1046/j.1600-6143.2004.00606.x

The Impact of Transplantation with Deceased Donor Hepatitis C-Positive

Kidneys on Survival in Wait-Listed Long-term Dialysis Patients

C. Abbotta,*, Krista L. Lentineb, Jay R. Buccia, Lawrence Y. Agodoac,

G. sd and Mark A. Schnitzlerb

Whether transplantation of deceased donor kidney allografts from donors with

antibodies against hepatitis C virus (HCV) confers a survival advantage

compared with remaining on the kidney transplant waiting list is not yet

known. We studied 38,270 USRDS Medicare beneficiaries awaiting kidney

transplantation who presented with end-stage renal disease from April 1,

1995 to July 31, 2000. regression was used to compare the adjusted

hazard ratios for death among recipients of kidneys from deceased donors,

and donors with antibodies against hepatitis C (DHCV+), controlling for

demographics and comorbidities. In comparison to staying on the waiting

list, transplantation from DHCV+ was associated with improved survival among

all patients (adjusted hazard ratio for death 0.76, 95% CI 0.60, 0.96). Of

patients receiving DHCV+ kidneys, 52% were themselves hepatitis C antibody

positive (HCV+), so outcomes associated with use of these grafts may have

particular implications for HCV+ transplant candidates. Recommendations for

use of DHCV+ kidneys may require analysis of data not currently collected

from either dialysis or transplant patients. However, transplantation of

DHCV+ kidneys is associated with improved patient survival compared to

remaining wait-listed and dialysis dependent.